Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Using clinical trial data to tailor adjuvant treatments for individual patients.

Regan MM, Gelber RD,

IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, 44 Binney Street, Boston, MA 02115, USA.

The 2005 St. Gallen Consensus Panel provided recommendations for the treatment of early breast cancer which rely on target identification first. The foremost advance since 2005-demonstration of trastuzumab efficacy for patients with HER2-positive disease-was realized because an effective treatment was being evaluated and because the trial patients had the targeted disease as determined by quality-controlled assessment prior to study entry. The BIG 1-98 trial provides a striking reminder of patients' benefit from reliable pathological tumor assessment so that targeted therapies are effectively utilized. Several statistical methods facilitate use of clinical trial data for individualizing treatment. Subgroup analyses summarized using forest plots are essential for better understanding the disease and its treatment. The HERA trial illustrates the interpretation of relative and absolute treatment effects and estimating hazard rates over time as means to distinguish relevant differences across subgroups. Overview analyses, joint analyses, the STEPP (subpopulation treatment effect pattern plot) method and recursive partitioning are valuable tools.

Published 6 November 2007 in Breast, 16: 98-104.
Full-text of this article is available online (may require subscription).

© 2004-2008 Herceptin Research Today. All Rights Reserved.